Ubisoft, Ambloytech bring gaming to healthcare

Cara Livernois | | Health Exec | Precision Medicine

Prescriptions for video games could be seen as a child’s dream medication—and now that dream could becoming reality. Amblyotech partnered with Ubisoft to develop the Amblyopad, a gaming system awaiting FDA approval to treat amblyopia.

Current methods of treating amblyopia (also known as lazy eyes) often involve wearing an eye patch for months. Noted for gaming titles such as Assassins Creed and Far Cry, Ubisoft has developed the games Dig Rush and Monster Burner to train eyes into coordination.

Read the full story by clicking below: 

Ubisoft's Dig Rush Video Game May Become Just What The Doctor Ordered

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Reimbursement update: What hospitals need to know about new Medicare payments for cardiac CT

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Cardiovascular Business
Stryker acquires Inari Medical for $4.9B

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.